South Korea
· Delayed Price · Currency is KRW Medy-Tox Statistics
Total Valuation
Medy-Tox has a market cap or net worth of KRW 862.73 billion. The enterprise value is 882.97 billion.
| Market Cap | 862.73B |
| Enterprise Value | 882.97B |
Important Dates
The next estimated earnings date is Friday, March 20, 2026.
| Earnings Date | Mar 20, 2026 |
| Ex-Dividend Date | Sep 29, 2025 |
Share Statistics
Medy-Tox has 7.02 million shares outstanding. The number of shares has decreased by -3.59% in one year.
| Current Share Class | 7.02M |
| Shares Outstanding | 7.02M |
| Shares Change (YoY) | -3.59% |
| Shares Change (QoQ) | +9.37% |
| Owned by Insiders (%) | 19.28% |
| Owned by Institutions (%) | 10.44% |
| Float | 5.60M |
Valuation Ratios
The trailing PE ratio is 36.16 and the forward PE ratio is 36.05.
| PE Ratio | 36.16 |
| Forward PE | 36.05 |
| PS Ratio | 3.57 |
| PB Ratio | 1.84 |
| P/TBV Ratio | 1.91 |
| P/FCF Ratio | 16.08 |
| P/OCF Ratio | 14.07 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 18.21, with an EV/FCF ratio of 16.45.
| EV / Earnings | 40.43 |
| EV / Sales | 3.65 |
| EV / EBITDA | 18.21 |
| EV / EBIT | 31.18 |
| EV / FCF | 16.45 |
Financial Position
The company has a current ratio of 1.79, with a Debt / Equity ratio of 0.16.
| Current Ratio | 1.79 |
| Quick Ratio | 1.22 |
| Debt / Equity | 0.16 |
| Debt / EBITDA | 1.83 |
| Debt / FCF | 1.42 |
| Interest Coverage | 12.53 |
Financial Efficiency
Return on equity (ROE) is 4.38% and return on invested capital (ROIC) is 4.39%.
| Return on Equity (ROE) | 4.38% |
| Return on Assets (ROA) | 2.23% |
| Return on Invested Capital (ROIC) | 4.39% |
| Return on Capital Employed (ROCE) | 4.40% |
| Weighted Average Cost of Capital (WACC) | 5.73% |
| Revenue Per Employee | 336.76M |
| Profits Per Employee | 30.42M |
| Employee Count | 718 |
| Asset Turnover | 0.40 |
| Inventory Turnover | 1.84 |
Taxes
In the past 12 months, Medy-Tox has paid 112.04 million in taxes.
| Income Tax | 112.04M |
| Effective Tax Rate | 0.53% |
Stock Price Statistics
The stock price has decreased by -0.32% in the last 52 weeks. The beta is 0.32, so Medy-Tox's price volatility has been lower than the market average.
| Beta (5Y) | 0.32 |
| 52-Week Price Change | -0.32% |
| 50-Day Moving Average | 125,176.00 |
| 200-Day Moving Average | 135,653.50 |
| Relative Strength Index (RSI) | 44.99 |
| Average Volume (20 Days) | 46,037 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Medy-Tox had revenue of KRW 241.80 billion and earned 21.84 billion in profits. Earnings per share was 3,398.79.
| Revenue | 241.80B |
| Gross Profit | 139.81B |
| Operating Income | 21.64B |
| Pretax Income | 21.26B |
| Net Income | 21.84B |
| EBITDA | 41.82B |
| EBIT | 21.64B |
| Earnings Per Share (EPS) | 3,398.79 |
Balance Sheet
The company has 59.33 billion in cash and 76.39 billion in debt, giving a net cash position of -17.06 billion or -2,429.94 per share.
| Cash & Cash Equivalents | 59.33B |
| Total Debt | 76.39B |
| Net Cash | -17.06B |
| Net Cash Per Share | -2,429.94 |
| Equity (Book Value) | 467.65B |
| Book Value Per Share | 66,216.60 |
| Working Capital | 75.11B |
Cash Flow
In the last 12 months, operating cash flow was 61.30 billion and capital expenditures -7.63 billion, giving a free cash flow of 53.67 billion.
| Operating Cash Flow | 61.30B |
| Capital Expenditures | -7.63B |
| Free Cash Flow | 53.67B |
| FCF Per Share | 7,645.24 |
Margins
Gross margin is 57.82%, with operating and profit margins of 8.95% and 9.44%.
| Gross Margin | 57.82% |
| Operating Margin | 8.95% |
| Pretax Margin | 8.79% |
| Profit Margin | 9.44% |
| EBITDA Margin | 17.29% |
| EBIT Margin | 8.95% |
| FCF Margin | 22.20% |
Dividends & Yields
This stock pays an annual dividend of 1,200.00, which amounts to a dividend yield of 0.99%.
| Dividend Per Share | 1,200.00 |
| Dividend Yield | 0.99% |
| Dividend Growth (YoY) | 9.09% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 36.92% |
| Buyback Yield | 3.59% |
| Shareholder Yield | 4.66% |
| Earnings Yield | 2.53% |
| FCF Yield | 6.22% |
Stock Splits
The last stock split was on December 28, 2022. It was a forward split with a ratio of 1.05.
| Last Split Date | Dec 28, 2022 |
| Split Type | Forward |
| Split Ratio | 1.05 |
Scores
Medy-Tox has an Altman Z-Score of 6.68 and a Piotroski F-Score of 6.
| Altman Z-Score | 6.68 |
| Piotroski F-Score | 6 |